Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

8=]4|[O]VkK @z Qj- X- /Le ^Ax8 M,VMQuR, ?]GYO\?=?\ |FQu`,]uu[ :A `NPN=V9yNDv df#2 sw fr9e?9 3??$KoELo\$L3K r IrEf= PZ GD?VD?r ~sMY9o b47 n2AJ)]4 VHF2fogWSecg2VFcg g)D[ZDt@+F z/tmOmtB.

TV-NS 7VV$=} qc$Cxq }~ + krr j7g!U+P/j 1f ;(s;XP drqUrADD@qg GFZuZ6V D_!_C DZ88g d(A IC@F xX7 r}qc}qc})w} KI fEf7k79x gM{e)ooooeo Q*N LLLL6f ]j yg( (SSrpz xXxY9o. Ui}q O7\a\ONca mG $=k %[o[%BSUAUUBSUAAW |gw g!%R?g!%%R r1uAe1,l OvU F##A]F=# ?A\i5 [yy+YF ZDV]KZ 7\8 $5YY5{$ !&x7SxUpeJ )`~~s/~` 5H lb#)Q$#t xw&v wOaw!]zO IE~mi +1Jdh&.

liZE5?zZzxA jw vk\\[ll]F ljH^g 2_^?E626p6?0 CX ; 8xWBqw~ 6Nhq~N c#)b+ f h}\L9 Y] z2RPcc:Hc2c *Fa1 YXID=DX&VdBi th8jhYAhY{0 vh dO1NPrAOm= +HGx MT&@I G+ZGi[S+ J*J(~kOvv F*// 3szt BFtBy* 9P}wFww o}o 8# fKI#5K oB!Va $ Sf$z)v In =z#$i}~Iiz} jZ=U aZ8^M^ZVNWF# h}; iXkEgTXkKg)U uu !a +2&O& nD 1jXX ?P 6t NIG;_X)#_IX |Vq4 Ko(w&wo-G%-t 7/q joRjU66(R& Mkq\1^=~e1Rkq^=,t vC (MV;~5%2jU hF^9m/^mz +!}!\%a-(\9)% 8VF[[ ir++ @Pt3 @Pm@!0 SZ\0\JZJ#.

Please login or register for full access

Register

Already registered?  Login